8-K: Liquidia Soars: YUTREPIA Drives Profitability in Q3

Liquidia Corporation reported strong third-quarter 2025 financial results, achieving profitability with $51.7 million in YUTREPIA net product sales and positive adjusted EBITDA.

Summary

• Net product sales of YUTREPIA reached $51.7 million for the three months ended September 30, 2025, marking the first full quarter of sales.
• Achieved profitability with $1.7 million in operating income for the quarter.
• Reported positive non-GAAP adjusted EBITDA of $10.1 million.
• Net loss significantly reduced to $3.5 million ($0.04 per basic and diluted share) in Q3 2025, compared to a net loss of $31.0 million ($0.40 per basic and diluted share) in Q3 2024.
• As of October 30, 2025, YUTREPIA has received more than 2,000 unique patient prescriptions and shipped to over 1,500 patients, supported by over 600 prescribers nationwide.
• Cash and cash equivalents totaled $157.5 million as of September 30, 2025, a decrease from $176.5 million as of December 31, 2024.
• Service revenue, net, was $2.7 million for Q3 2025, down from $4.4 million in Q3 2024, primarily due to lower sales volumes of Treprostinil Injection.
• Research and development expenses decreased by $2.6 million (21%) to $9.3 million, mainly due to a shift from R&D to YUTREPIA commercialization, partially offset by a $1.5 million increase in clinical expenses for the L606 program.
• Selling, general and administrative expenses increased by $19.9 million (98%) to $40.1 million, driven by higher headcount, commercialization support for YUTREPIA, and increased legal fees related to ongoing litigation.
• Total other expense, net, increased by $3.5 million to $5.3 million, primarily attributable to higher borrowings under the HCR Agreement.

Sentiment

Score: 8

Explanation: The company achieved profitability in its first full quarter of YUTREPIA sales, reported strong product revenue, significantly reduced its net loss, and demonstrated robust patient and prescriber uptake for its key product. While cash decreased and SG&A increased due to commercialization, these are expected during a product launch. The ongoing litigation is a notable risk, but the overall financial and operational performance is very positive.

Positives

• Achieved profitability in the first full quarter of YUTREPIA sales with $1.7 million in operating income.
• Recorded strong net product sales of YUTREPIA at $51.7 million, demonstrating significant launch momentum.
• Reported positive non-GAAP adjusted EBITDA of $10.1 million.
• Net loss dramatically reduced to $3.5 million in Q3 2025 from $31.0 million in Q3 2024.
• Strong patient and prescriber uptake for YUTREPIA, with over 2,000 unique prescriptions and 1,500 patient starts as of October 30, 2025, from over 600 prescribers.
• Continued investment in the L606 program, with a $1.5 million increase in clinical expenses for a planned global pivotal study for PH-ILD.

Negatives

• Cash and cash equivalents decreased to $157.5 million as of September 30, 2025, from $176.5 million as of December 31, 2024.
• Service revenue, net, decreased by $1.7 million to $2.7 million, primarily due to lower sales volumes of Treprostinil Injection.
• Selling, general and administrative expenses increased significantly by $19.9 million (98%) to $40.1 million, driven by commercialization costs and legal fees.
• Total other expense, net, increased by $3.5 million to $5.3 million, primarily due to higher borrowings under the HCR Agreement.

Risks

• The ability to maintain YUTREPIA's approval and continue commercialization is subject to ongoing litigation with United Therapeutics, which is seeking injunctive relief that could block sales for PAH and/or PH-ILD.
• Forward-looking statements involve significant risks and uncertainties, and actual results could differ materially from those expressed or implied.
• Operating in a very competitive and rapidly changing environment with inherent industry risks, including the emergence of new risks that management cannot predict.

Future Outlook

Management believes YUTREPIA has the potential to become the preferred inhaled prostacyclin for PAH and PH-ILD, supported by growing real-world evidence and broadening access. The company is well-positioned for sustained growth and continued profitability, while thoughtfully investing in programs to expand YUTREPIA's therapeutic profile and advance L606 into pivotal trials.

Management Comments

• "Our third quarter results demonstrate the continued momentum of YUTREPIA’s launch and the clear enthusiasm from both prescribers and patients." Dr. Roger Jeffs, CEO.
• "As of October 30, 2025, we have received more than 2,000 unique prescriptions and shipped to more than 1,500 patients, supported by over 600 prescribers nationwide." Dr. Roger Jeffs, CEO.
• "As our real-world evidence continues to grow and access broadens, we continue to believe in YUTREPIA’s potential to become the preferred inhaled prostacyclin to treat patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)." Dr. Roger Jeffs, CEO.
• "With the strong foundation established in our first full quarter post-launch, we are well positioned to pursue sustained growth and continued profitability, while thoughtfully investing in programs to expand YUTREPIA’s therapeutic profile and advance L606 into pivotal trials." Dr. Roger Jeffs, CEO.

Industry Context

The company operates in the rare, chronic, and progressive disease space of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). YUTREPIA competes as an inhaled dry-powder formulation of treprostinil, aiming to become the preferred treatment. The market for PH-ILD is significant, with over 60,000 estimated patients in the U.S., and treatments are relatively new, with inhaled treprostinil first approved for this indication in March 2021. The company also markets a generic treprostinil injection, competing with branded drugs like Remodulin.

Comparison to Industry Standards

• YUTREPIA is positioned as an inhaled dry-powder formulation of treprostinil, delivered via a convenient, low-effort, palm-sized device, designed for enhanced deposition in the lung using PRINT technology. This differentiates it from other treprostinil formulations, such as United Therapeutics' Remodulin (parenteral) and potentially other inhaled forms.
• The company's generic Treprostinil Injection is the first-to-file, fully substitutable generic for parenteral administration, directly competing with Remodulin (United Therapeutics) by offering the same active ingredient, strengths, dosage form, and inactive ingredients at a lower price.
• The L606 program, an investigational sustained-release liposomal treprostinil administered twice-daily with a next-generation nebulizer, aims to enhance drug exposure over an extended period, potentially offering a differentiated dosing regimen compared to existing or other investigational treprostinil therapies.
• The achievement of profitability in the first full quarter of YUTREPIA sales, with $51.7 million in net product sales, indicates a strong market reception and commercial execution, potentially outperforming typical launch trajectories for new rare disease therapies.

Legal Proceedings

• Ongoing YUTREPIA-related litigation with United Therapeutics in the U.S. District Court for the District of Delaware and U.S. District Court for the Middle District of North Carolina.
• United Therapeutics is seeking injunctive relief, which could block the ability to continue selling YUTREPIA for one or both of PAH and PH-ILD.

Stakeholder Impact

• Shareholders: Positive impact due to strong YUTREPIA sales, achievement of profitability, and significant reduction in net loss, potentially leading to increased shareholder value. However, ongoing litigation poses a risk to future sales and could negatively impact share price if injunctive relief is granted.
• Patients (PAH & PH-ILD): Continued access to YUTREPIA as a treatment option, with potential for expanded therapeutic profile and advancement of L606, offering future treatment alternatives.
• Prescribers: Continued availability and growing real-world evidence for YUTREPIA, supporting its use in treating PAH and PH-ILD.
• Employees: Increased headcount and shift of personnel from R&D to commercialization activities indicate growth and potential for new opportunities within the company.
• Creditors: Higher borrowings under the HCR Agreement indicate increased debt, but improved profitability and cash flow from YUTREPIA sales could enhance the company's ability to service this debt.

Next Steps

• Continue to pursue sustained growth and profitability for YUTREPIA.
• Thoughtfully invest in programs to expand YUTREPIA's therapeutic profile.
• Advance L606 into pivotal trials, specifically a planned global pivotal study for the treatment of PH-ILD.
• Host a webcast on November 3, 2025, at 8:30 a.m. ET to review financial performance and provide a corporate update.

Key Dates

Recommendation

The company has demonstrated exceptional performance in its first full quarter of YUTREPIA sales, achieving profitability and positive adjusted EBITDA, significantly reducing its net loss, and showing robust patient and prescriber adoption. This indicates strong commercial execution and market acceptance for a key product. While there is ongoing litigation risk, the current operational and financial momentum suggests a strong growth trajectory. The investment in L606 further strengthens the long-term pipeline. This filing presents a compelling case for a strong buy, assuming the litigation risk is manageable or already priced in.

Keywords

Liquidia Corporation, LQDA, YUTREPIA, treprostinil, pulmonary arterial hypertension, PAH, pulmonary hypertension associated with interstitial lung disease, PH-ILD, biopharmaceutical, financial results, Q3 2025, net product sales, profitability, adjusted EBITDA, L606, clinical trials, SEC filing, 8-K